[go: up one dir, main page]

EE200100146A - Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine - Google Patents

Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine

Info

Publication number
EE200100146A
EE200100146A EEP200100146A EEP200100146A EE200100146A EE 200100146 A EE200100146 A EE 200100146A EE P200100146 A EEP200100146 A EE P200100146A EE P200100146 A EEP200100146 A EE P200100146A EE 200100146 A EE200100146 A EE 200100146A
Authority
EE
Estonia
Prior art keywords
alpha
subunit integrin
subunit
integrin
multiple myeloma
Prior art date
Application number
EEP200100146A
Other languages
English (en)
Inventor
R. Mundy Gregory
Yoneda Toshiyuki
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of EE200100146A publication Critical patent/EE200100146A/et
Publication of EE05558B1 publication Critical patent/EE05558B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
EEP200100146A 1998-09-14 1999-09-13 Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks EE05558B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (2)

Publication Number Publication Date
EE200100146A true EE200100146A (et) 2002-06-17
EE05558B1 EE05558B1 (et) 2012-08-15

Family

ID=22278506

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100146A EE05558B1 (et) 1998-09-14 1999-09-13 Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks

Country Status (28)

Country Link
US (1) US7211252B2 (et)
EP (2) EP2065050A1 (et)
JP (3) JP2002524529A (et)
KR (1) KR100628818B1 (et)
CN (1) CN1236815C (et)
AT (1) ATE418999T1 (et)
AU (1) AU757873B2 (et)
BR (1) BR9913705A (et)
CA (1) CA2343579C (et)
CY (1) CY1109413T1 (et)
CZ (1) CZ302997B6 (et)
DE (1) DE69940206D1 (et)
DK (1) DK1113810T3 (et)
EA (1) EA004270B1 (et)
EE (1) EE05558B1 (et)
ES (1) ES2319831T3 (et)
HU (1) HU229038B1 (et)
IL (2) IL141877A0 (et)
IS (1) IS2631B (et)
NO (2) NO327855B1 (et)
NZ (1) NZ511062A (et)
PL (1) PL203114B1 (et)
PT (1) PT1113810E (et)
SI (1) SI1113810T1 (et)
SK (1) SK287601B6 (et)
TR (1) TR200100734T2 (et)
WO (1) WO2000015247A2 (et)
ZA (1) ZA200102032B (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2263485T3 (es) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2002356180A1 (en) * 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
EP2394652A3 (en) * 2004-02-06 2012-10-24 Elan Pharmaceuticals Inc. Methods and compositions for treating tumors and metastatic disease
US8808698B2 (en) * 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3042668B1 (en) * 2006-06-07 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
EP3202789B1 (en) * 2010-04-16 2020-05-06 Biogen MA Inc. Anti-vla-4 antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140135483A1 (en) * 2011-06-30 2014-05-15 Gene Techno Science Co., Ltd. Soluble integrin alpha-4 mutant
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ES2103468T3 (es) 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
CA2155303C (en) 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
HU220799B1 (hu) * 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
US6692742B1 (en) 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
CZ298413B6 (cs) * 1998-05-28 2007-09-26 Biogen Idec Ma Inc. Beta-Alaninový derivát, farmaceutická kompozice tento derivát obsahující a použití tohoto derivátu pro prípravu léciva
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
KR100628818B1 (ko) 2006-09-27
ZA200102032B (en) 2002-11-07
CA2343579C (en) 2012-05-29
US7211252B2 (en) 2007-05-01
IL197686A0 (en) 2011-07-31
JP2002524529A (ja) 2002-08-06
EP1113810A2 (en) 2001-07-11
ES2319831T3 (es) 2009-05-12
US20020022028A1 (en) 2002-02-21
CZ2001916A3 (cs) 2001-08-15
SK6052001A3 (en) 2001-12-03
SI1113810T1 (sl) 2009-04-30
WO2000015247A8 (en) 2009-12-23
NO327855B1 (no) 2009-10-05
ATE418999T1 (de) 2009-01-15
NZ511062A (en) 2003-04-29
IL141877A0 (en) 2002-03-10
PL347128A1 (en) 2002-03-25
PL203114B1 (pl) 2009-08-31
JP5378303B2 (ja) 2013-12-25
EA004270B1 (ru) 2004-02-26
HU229038B1 (hu) 2013-07-29
WO2000015247A2 (en) 2000-03-23
JP2013241441A (ja) 2013-12-05
BR9913705A (pt) 2001-06-05
CZ302997B6 (cs) 2012-02-15
AU6248699A (en) 2000-04-03
AU757873B2 (en) 2003-03-06
HUP0103630A2 (hu) 2002-01-28
CY1109413T1 (el) 2014-08-13
CN1321091A (zh) 2001-11-07
CN1236815C (zh) 2006-01-18
TR200100734T2 (tr) 2001-07-23
EP1113810B1 (en) 2008-12-31
CA2343579A1 (en) 2000-03-23
WO2000015247A3 (en) 2000-05-25
NO20011283D0 (no) 2001-03-14
DE69940206D1 (de) 2009-02-12
IS5856A (is) 2001-02-23
NO20011244L (no) 2001-05-14
KR20010085793A (ko) 2001-09-07
IS2631B (is) 2010-06-15
PT1113810E (pt) 2009-03-10
JP2010235620A (ja) 2010-10-21
HUP0103630A3 (en) 2004-03-01
NO20011244D0 (no) 2001-03-12
DK1113810T3 (da) 2009-04-06
EP2065050A1 (en) 2009-06-03
EA200100362A1 (ru) 2001-12-24
SK287601B6 (sk) 2011-03-04
HK1038313A1 (en) 2002-03-15
EE05558B1 (et) 2012-08-15

Similar Documents

Publication Publication Date Title
EE200100146A (et) Alfa-4 subühikut kandva integriini ja alfa-4 subühikut kandva integriini ligandi vahelise interaktsiooni antagonisti kasutamine
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
DE60038239D1 (de) Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie
ATE543509T1 (de) Material und verfahren zur förderung der reparatur von nervengewebe
BR0007875A (pt) Uso de um antagonista de integrina para inibir crescimento de tumor cerebral
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
TR199701356A2 (xx) L�kozit adhasyonu inhibit�rleri ve VLA-4-antagonistleri olarak heterosiklenler.
ES2105408T3 (es) Piridilmetilpiridonas sustituidas como antagonistas de angiotensina ii.
DE3772121D1 (de) Abtastendoskop zur chirurgischen verwendung.
ATE234812T1 (de) Integrin antagonisten
NO2019032I1 (no) Treosulfan
EP0635263A3 (en) Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DE60033416D1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
EP2236619A3 (en) BCL2L12 polypeptide activators and inhibitors
DK1194158T3 (da) Anvendelse af UK 114-proteiner til hæmning af organtransplantatafstödning
MX9302324A (es) Antagonistas de endotelina ii.
ES1041670Y (es) Disposicion perfeccionada para la fijacion de baldas y pilares.
IT8745734A0 (it) Contenitore, in particolare in polipropilene alveolare e materiali vari, per la raccolta protetta di strumenti e mezzi sanitari usati.
ITBO960037A0 (it) Composizione e procedimento per la sterilizzazione di substrati di coltura

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20150913